Recent studies investigate Phexxi for various potential indications
Bassem Maximos, MD, MPH, FACOG, discusses 2 recent studies investigating nonhormomal contraceptive gel Phexxi (Evofem Biosciences) for the potential treatment of UTIs and improvement in sexual satisfaction.
**Editors note: In an earlier version of this video, Dr. Maximos explained that 77% of women on study/using Phexxi suffered a UTI. The data actually shows that 77 women out of 1339 study subjects suffered a UTI, a notable decrease in UTIs in women using Phexxi. The video has since been edited to reflect this correction.
FDA approves Visby’s test for at-home STI identification
Published: March 28th 2025 | Updated: March 28th 2025The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.
Read More
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
